863-P: In Patients without Diabetes, Glycemic Variability Derived from Continuous Glucose Monitoring (CGM) Data Relates to Hyperglycemia More Than Insulin Resistance

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 863-P
Author(s):  
YUAN ZHANG ◽  
EVAN A. OLAWSKY ◽  
ALISON C. ALVEAR ◽  
LYNN E. EBERLY ◽  
LISA S. CHOW
Keyword(s):  
Insulin Resistance ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glycemic Variability

Glycemic Variability and Insulin Needs in Patients with Type 1 Diabetes Mellitus Supplemented with Vitamin D: A Pilot Study Using Continuous Glucose Monitoring System

2018 ◽  
Vol 14 (4) ◽  
pp. 395-403 ◽  
Author(s):  
Karem Mileo Felício ◽  
Ana Carolina Contente Braga de Souza ◽  
Joao Felicio Abrahao Neto ◽  
Franciane Trindade Cunha de Melo ◽  
Carolina Tavares Carvalho ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Vitamin D ◽  
Type 1 Diabetes ◽  
Pilot Study ◽  
Type 1 Diabetes Mellitus ◽  
Monitoring System ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glycemic Variability

scholarly journals Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Fumi Uemura ◽  
Yosuke Okada ◽  
Keiichi Torimoto ◽  
Yoshiya Tanaka
Keyword(s):  
Glucose Level ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
High Dose ◽  
Type 2 Diabetics ◽  
Time In Range ◽  
The Difference ◽  
Glycated Hemoglobin Level

AbstractTime in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value.

Resistance to Data Loss of Glycemic Variability Measurements in Long-Term Continuous Glucose Monitoring

2018 ◽  
Vol 20 (12) ◽  
pp. 833-842 ◽  
Author(s):  
Przemysław Kucharski ◽  
Konrad Pagacz ◽  
Agnieszka Szadkowska ◽  
Wojciech Młynarski ◽  
Andrzej Romanowski ◽  
...  
Keyword(s):  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
Data Loss

scholarly journals Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes

2016 ◽  
Vol 18 (7) ◽  
pp. 629-636 ◽  
Author(s):  
Christine L. Chan ◽  
Laura Pyle ◽  
Megan M. Kelsey ◽  
Lindsey Newnes ◽  
Amy Baumgartner ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
Glycemic Markers
Sign in / Sign up

Export Citation Format

Share Document